These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 38306629)

  • 21. Safety Standards in Pharmaceutical Compounding, Part 1: The Occupational Safety and Health Administration.
    Greeson NMH; Mixon W; Allan WC
    Int J Pharm Compd; 2020; 24(4):270-276. PubMed ID: 32649298
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluating containment effectiveness of A2 and B2 biological safety cabinets.
    Taylor AV; Baker N; Hulsey M; Bennett CC; Meiners M; Gonzales BA
    Am J Health Syst Pharm; 2019 Apr; 76(9):599-607. PubMed ID: 31361829
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of Three Commercial Disinfectants in Reducing Microbial Surfaces' Contaminations of Pharmaceuticals Hospital Facilities.
    Di Martino G; Pasqua S; Douradinha B; Monaco F; Di Bartolo C; Conaldi PG; D'Apolito D
    Int J Environ Res Public Health; 2021 Jan; 18(2):. PubMed ID: 33477614
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of United States Pharmacopeia chapter 797: results of a national survey.
    Candy TA; Schneider PJ; Pedersen CA
    Am J Health Syst Pharm; 2006 Jul; 63(14):1336-43. PubMed ID: 16809754
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Blueprint for implementing USP chapter 797 for compounding sterile preparations.
    Kastango ES;
    Am J Health Syst Pharm; 2005 Jun; 62(12):1271-88. PubMed ID: 15947127
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Explanations and unresolved issues pertaining to the development of the Nuclear Pharmacy Compounding Guidelines.
    Hung JC; Augustine SC; Cheng KT; Green RL; Hopkins WM; Laven DL; Nelson BR; Petry NA; Ponto JA; Quinton TM; Swanson DP
    J Am Pharm Assoc (Wash); 2002; 42(5):789-98. PubMed ID: 12269713
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dry-heat Depyrogenation Ovens for Pharmaceutical Compounding Facilities.
    Weller T; Kragseth R; Dullinger R; Illum H; Perry A
    Int J Pharm Compd; 2015; 19(3):182-92. PubMed ID: 26714359
    [TBL] [Abstract][Full Text] [Related]  

  • 28. USP <800>: Key Considerations and Changes for Health Systems.
    Sahadeo P; Weber RJ
    Hosp Pharm; 2015 Nov; 50(10):941-949. PubMed ID: 27729683
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tips for cleanroom construction and renovation.
    Mixon W; Huffman L
    Int J Pharm Compd; 2009; 13(2):100-4. PubMed ID: 23970002
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Primary Engineering Controls in Pharmaceutical Compounding, Part 1: Unidirectional-airflow Workstations, Compounding Aseptic Isolators, and Compounding Aseptic Containment Isolators.
    Mulder K
    Int J Pharm Compd; 2019; 23(6):447-452. PubMed ID: 31751940
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of a sterile compounding training and competency program at a large academic medical center.
    Penzien CE; Tharp JC; Mulzer K; Rurka C; Abbas C; Chaffee BW
    Am J Health Syst Pharm; 2020 Dec; 77(24):2089-2100. PubMed ID: 33179045
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacy compounding of high-risk level products and patient safety.
    Mullarkey T
    Am J Health Syst Pharm; 2009 Sep; 66(17 Suppl 5):S4-13. PubMed ID: 19710449
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Basics of compounding: considerations for implementing United States pharmacopeia chapter 797 pharmaceutical compounding-sterile preparations, part 15: personnel training, cleansing, and garbing.
    Okeke CC; Allen LV
    Int J Pharm Compd; 2009; 11(5):420-6. PubMed ID: 23966526
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of ATP bioluminescence for monitoring surface hygiene in a hospital pharmacy cleanroom.
    Tršan M; Vehovc M; Seme K; Srčič S
    J Microbiol Methods; 2020 Jan; 168():105785. PubMed ID: 31770539
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Laboratory considerations of United States Pharmacopeia Chapter <71> sterility tests and its application to pharmaceutical compounding.
    Hyde TD
    Int J Pharm Compd; 2014; 18(1):46-52. PubMed ID: 24881341
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Choosing a Vial Processing Line for Aseptic Compounding: Part 1.
    Noorian S; Vahedi N
    Int J Pharm Compd; 2016; 20(4):283-292. PubMed ID: 28333673
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potential risks of pharmacy compounding.
    Gudeman J; Jozwiakowski M; Chollet J; Randell M
    Drugs R D; 2013 Mar; 13(1):1-8. PubMed ID: 23526368
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Basics of Sterile Compounding. Quality Assurance and Quality Control: Being Prepared for U.S. Food and Drug Administration Inspections and Staying in Compliance with United States Pharmacopeia Chapter <797>: Part 2.
    Martin M
    Int J Pharm Compd; 2018; 22(6):475-478. PubMed ID: 30384348
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quality-control analytical methods: aqua pura: water purification systems and United States pharmacopeia waters for the compounding pharmacy, part 1.
    Latta KS; Cabaleiro J; Whitehead P; Edison D
    Int J Pharm Compd; 2011; 15(2):133-44. PubMed ID: 23696083
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.